Physician Assistant Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Mark Mashita

Physician Assistant, Surgical Everett, WA Physician Assistant

NPI 1245412535 CMS profile 10678968

1100 Pacific Ave Ste 300, Everett, WA 98201

Open in the dashboard

General payments

$16,396

71 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Mark Mashita of Everett, WA is reported in the CMS Open Payments database as having received $16,396 across 71 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 98th percentile of Physician Assistant, Surgical profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $3,681 20
2024 General $5,119 23
2023 General $3,254 13
2022 General $4,324 14
2021 General $18 1

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Mark Mashita
  • Physician Assistant, Surgical median
  • Middle half of Physician Assistant, Surgical
  • National median

In program year 2025, general payments to Mark Mashita were reported at $3,681. Among 8,152 Physician Assistant, Surgical profiles paid that year, the median was $146 and the middle half received between $51 and $385.

Show as a table
Year Mark Mashita Physician Assistant, Surgical median Middle half National median
2019 $0 — — $163
2020 $0 — — $114
2021 $18 $111 $36–$285 $132
2022 $4,324 $126 $44–$350 $149
2023 $3,254 $137 $47–$355 $160
2024 $5,119 $146 $49–$384 $164
2025 $3,681 $146 $51–$385 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. Smith+Nephew, Inc. $14,384 63 payments
  2. Pacira Pharmaceuticals Incorporated $1,927 5 payments
  3. Avanos Medical $32 1 payment
  4. Fidia Pharma USA Inc. $27 1 payment
  5. Orthofix Medical, Inc. $25 1 payment

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Travel and Lodging $12,581 28 payments
  2. Food and Beverage $3,815 43 payments
Products named General payments · program years 2021–2025
  1. JOURNEY II Recon Knees $7,975 29 payments
  2. REAL INTELLIGENCE $7,177 38 payments
  3. LEGION Revision $5,274 18 payments
  4. RI Hip Navigation $5,115 16 payments
  5. JOURNEY $4,594 12 payments
  6. OR3O Dual Mobility $3,395 8 payments
  7. REDAPT $2,996 10 payments
  8. TANDEM $2,400 8 payments
  9. JOURNEY II Recon Knees $2,023 10 payments
  10. POLARSTEM $1,965 5 payments
  11. Other $5,527 24 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 7 drugs

Part D claims

362

Median for Physician Assistant: 241

Drug cost

$3,095

Median for Physician Assistant: $4,110

Branded share of claims

64.4%

Median for Physician Assistant: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Oxycodone-Acetaminophen Oxycodone Hcl/Acetaminophen Brand 96 $1,064
Ondansetron Odt Ondansetron Brand 93 $1,011
Hydroxyzine Pamoate Generic 73 $347
Hydrocodone-Acetaminophen Hydrocodone/Acetaminophen Brand 31 $315
Meloxicam Generic 42 $184
Diclofenac Sodium Er Diclofenac Sodium Brand 13 $151
Amoxicillin Generic 14 $23

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 114,276 Part D prescribers listed as Physician Assistant; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 28 billing codes

Paid by Medicare

$40,255

Of which drugs: $5,031

Medicare patients

210

Average age 76

Services billed

1,923

128 women, 82 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
Arthritis 75%
High blood pressure 70%
Chronic kidney disease 28%
Depression 25%
Diabetes 22%
Ischemic heart disease 21%
Atrial fibrillation 18%
Cancer 14%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Hyaluronan or derivative, hyalgan, supartz or visco-3, for intra-articular injection, per dose J7321 Office 16 56 $3,121
Injection, methylprednisolone acetate, 1 mg J1010 Office 21 1,000 $102

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

71 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Physician Assistant, Surgical in Washington

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record